Key Highlights

● Kardigan listed on June 18, 2026 at $16.00 per share, raising roughly $400 million, and traded near $18.50 with a market Capitalization around $1.73 billion by mid-September 2026.

● Scribe Therapeutics dosed the first patient in a Phase 1 trial of its CRISPR-based cholesterol candidate STX-1150 on September 2, 2026, trading near a $550 million market capitalization.

● Mobia Medical is the only revenue-generating name in the group, with trailing Revenue of about $45 million and its FDA-approved Vivistim vagus nerve stimulation system now included in 2026 American Heart Association stroke-rehabilitation guidance.

● US biotechnology companies completed 21 IPOs raising roughly $7.85 billion by August 18, 2026, the strongest showing since 2021, with year-to-date financing activity reaching about $51.04 billion across 348 deals.

Five newly public healthcare names, from cardiovascular drug developers to a CRISPR gene-editing pioneer and a neurostimulation device maker, capture why the 2026 biotech reopening has become one of the Nasdaq Composite's defining sub-themes. Here is what each company actually is, and what to watch next.

The Reopening Everyone Was Waiting For

After a multi-year drought, the initial public offering window for life sciences swung open in 2026, and the Nasdaq Composite has been the primary stage. The five tickers in this basket, Kardigan, Scribe Therapeutics, Mobia Medical, Braveheart Bio and Turn Therapeutics, are all verifiable Nasdaq-listed healthcare companies, and four of the five debuted this year. They span three distinct corners of the sector: cardiovascular drug development, genetic medicine, and medical devices.

Most of these companies are pre-revenue or barely revenue-generating, deeply loss-making, and priced on promise rather than profit. This is a map of a theme and its risks, not a buy list.

A Backdrop of Record Capital and Renewed Appetite

The context matters more than any single stock. According to market data, US biotechnology companies completed 21 IPOs raising roughly $7.85 billion by 18 August 2026, the strongest showing since 2021. Add follow-on offerings and convertible Debt and the year-to-date tally reached about 348 deals worth some $51.04 billion.

Three drivers are usually cited: clinical programs that matured while companies waited out the downturn, a wave of pharma M&A driven by looming Patent cliffs, and the return of specialist and generalist healthcare investors.

Prices, market caps and analyst views that follow come from data aggregators as of mid-September 2026 and should be treated as snapshots, not fixed values.

Kardigan (NASDAQ:KARD): The $400 Million Cardiovascular Debut

Kardigan, Inc. is a clinical-stage biopharmaceutical company developing medicines aimed at the underlying biology of cardiovascular disease, including primary and secondary cardiomyopathies. It listed on 18 June 2026, pricing at $16.00 and raising roughly $400 million in an upsized offering, one of the year's larger biotech IPOs.

The company had built toward this moment, closing a $254 million Series B in October 2025 to advance a late-stage portfolio of personalized cardiovascular medicines. Its pipeline is anchored by candidates including danicamtiv and ataciguat, with the company having flagged multiple presentations at the ACC.26 cardiology meeting.

As of mid-September 2026, aggregator data put the shares near $18.50 and market capitalization around $1.73 billion, on roughly 93.5 million shares, with heavy losses typical of a pre-commercial drugmaker.

The bull case rests on the sheer size of the cardiovascular market and a portfolio described as late-stage. The obvious risk is binary trial outcomes: pivotal readouts are anticipated in 2027, so much of 2026 is a waiting game, and that timing may still shift.

Scribe Therapeutics (NASDAQ:SCTX): CRISPR Meets Cardiometabolic Disease

Scribe Therapeutics Inc. is a clinical-stage genetic-medicines company based in Alameda, California, applying CRISPR-based editing to cardiometabolic disease. It went public on 24 July 2026, with reporting indicating an IPO price around $15 that traded sharply higher on debut.

The programs are the story. Scribe has described STX-1150, an epigenetic-silencing approach to cholesterol reduction; STX-1200, a gene-editing candidate targeting elevated lipoprotein(a); and an additional program, STX-1400. Notably, the company reported dosing the first patient in a Phase 1 trial of STX-1150 on 2 September 2026, a genuine near-term catalyst rather than a distant promise.

Aggregator figures in mid-September showed shares near $29 and a market capitalization around $550 million, with trailing revenue of roughly $33 million reflecting collaboration income rather than product sales.

Scribe sits at the speculative frontier. Genetic-medicine platforms carry both durability appeal, a potential one-and-done edit, and outsized safety and Manufacturing risk. Early clinical data will define sentiment; a first-in-human program means the safety bar, not efficacy, is the first hurdle.

Mobia Medical (NASDAQ:MOBI): The Device Outlier With Real Revenue

Mobia Medical, Inc. is the odd one out, a medical-device company rather than a drug developer. It listed on 8 May 2026 and focuses on neurostimulation for neurological conditions. Its flagship, the Vivistim System, is described as an FDA-approved implantable device pairing vagus nerve stimulation with rehabilitation therapy to improve upper-limb motor function in post-stroke patients.

Crucially, Mobia Medical already has commercial traction. Aggregator data listed trailing revenue of about $45 million, up sharply year on year, alongside a market capitalization near $333 million on roughly 33.3 million shares and continuing net losses as it scales. Reported clinical validation includes inclusion of paired VNS in updated 2026 American Heart Association stroke-rehabilitation guidance and two-year follow-up data published in a peer-reviewed neurology journal.

For investors who find pre-revenue biotech uninvestable, Mobia Medical offers something rarer in this cohort: an approved product, a reimbursement pathway forming, and a growth rate. The risks are commercial-execution risks, adoption pace, payer coverage and cash burn, rather than pure clinical binaries.

Braveheart Bio (NASDAQ:BRVE): A Focused Bet on Hypertrophic Cardiomyopathy

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company, incorporated in 2026 and headquartered in San Francisco, developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It debuted on 6 August 2026, pricing an upsized offering of 21.25 million shares at $18.00.

Its lead candidate is BHB-1893 (also referenced as HRS-1893), an oral small-molecule cardiac myosin inhibitor, with Phase III work underway across obstructive and non-obstructive HCM. That places Braveheart Bio in a validated but competitive mechanistic class, chasing established myosin-inhibitor therapies.

Mid-September aggregator data showed shares near $27, a market capitalization around $1.74 billion, and, importantly for a clinical-stage name, a reported cash position of roughly $527 million after financing, against a lean headcount. A strong Balance Sheet buys runway through expensive Phase III trials.

The watch item is straightforward: pivotal HCM data. A me-too myosin inhibitor must show either differentiated efficacy, a cleaner safety or titration profile, or broader label potential to justify its valuation.

Turn Therapeutics (NASDAQ:TTRX): The Smallest, Most Speculative Name, Framed Honestly

Turn Therapeutics Inc. requires the most careful framing. Unlike the others, it did not run a capital-raising IPO in 2026: it completed a direct listing on Nasdaq on 8 October 2025, registering shares for existing holders and raising no new money. It was formerly Global Health Solutions, Inc. and renamed itself in September 2025.

The company develops treatments for inflammatory skin, nail and eye conditions using a proprietary PermaFusion process; its Hexagen product line holds prior FDA clearances. Its lead clinical asset, GX-03, is in Phase 2 for atopic dermatitis, with a readout targeted for the fourth quarter of 2026. In September 2026 it announced high-profile scientific hires, including former CDC Director Robert Redfield and former FDA Commissioner Stephen Hahn in advisory and Leadership roles.

Investors should note the scale. Aggregator data listed a reported headcount of just two, a share price near $13 and a market capitalization around $400 million. A roughly $400 million valuation on a two-person, pre-approval company financed via direct listing is, by any conventional measure, richly speculative and thinly resourced. Treat it as the highest-risk entry here.

What Investors Should Watch

Catalysts cluster in the coming months. Turn Therapeutics has a GX-03 Phase 2 atopic-dermatitis readout targeted for Q4 2026, the nearest hard data point. Scribe Therapeutics will generate early Phase 1 safety signals from STX-1150. Braveheart Bio's Phase III HCM program and Kardigan's pivotal readouts, guided toward 2027, are the larger, later prizes. Mobia Medical's story is commercial: revenue trajectory, guideline-driven adoption and cash burn. Program facts are confirmed; the exact timing can still slip.

Watch the plumbing, too. Newly listed micro- and small-caps are exposed to lock-up expirations, follow-on dilution, and, for the smallest names, Nasdaq minimum-bid-price and listing-compliance rules if shares fall. None of the five currently shows a going-concern or delisting notice in the sources reviewed, but that can change quickly for pre-revenue issuers.

Four Pre-Revenue Bets and One Commercial Outlier

The theme is real: 2026 reopened the biotech IPO market, and the Nasdaq Composite is where these companies trade. Kardigan and Braveheart Bio represent well-capitalized cardiovascular bets; Scribe Therapeutics is a genetic-medicine frontier play; Mobia Medical is the revenue-generating device outlier; and Turn Therapeutics is the small, speculative direct-listing story that must be judged on its own terms. But a theme to watch is not a theme to buy. Four of five are pre-revenue and heavily loss-making, valuations lean on catalysts that have not yet landed, and the next two quarters of clinical and commercial data will separate the durable stories from the hype.